Sterling Capital Management
GPCR icon

Sterling Capital Management’s Structure Therapeutics GPCR Stock Holding History

Sterling Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$105K Buy
3,345
+1,300
+64% +$61K ﹤0.01% 1409
2026
Q2 		$110K Buy
2,045
+1,455
+247% +$64.4K ﹤0.01% 1374
2026
Q1 		$28.4K Buy
+590
New +$40.4K ﹤0.01% 1860

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Pacific Heights Asset Management
Pacific Heights Asset Management San Francisco, California $3.1B AUM 37.54% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.3B AUM 33.78% 1-Year Est. Return
Peregrine Capital Management
Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Sterling Capital Management's GPCR Position: Q3 2026 in Review

Sterling Capital Management increased its Structure Therapeutics (GPCR) stake by 64% in Q3 2026, buying an estimated $61K and bringing the position to 3,345 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #1409.

Sterling Capital Management first reported a position in GPCR in Q1 2026 and has held it in 3 quarters since. The position peaked at $110K in Q2 2026. 60 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Sterling Capital Management held 3,345 shares of Structure Therapeutics worth $105K as of Q3 2026.
  • Sterling Capital Management bought 1,300 Structure Therapeutics shares in Q3 2026, an estimated $61K.
  • Structure Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1409 holding.
  • Sterling Capital Management first reported a position in Structure Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Sterling Capital Management's Structure Therapeutics position peaked at $110K in Q2 2026.
  • 60 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.